Neuroendocrine Tumor Treatment Market to Surpass US $2.9 Billion by 2025 - Underpinned by Increasing Incidence of GI and Lung Neuroendocrine Tumors
Increasing cases of Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia type 2 (MEN2), Neurofibromatosis type 1 (NF1), Von Hippel-Lindau syndrome (VHL), and Tuberous sclerosis complex (TSC) disease leads to high incidence and prevalence of neuroendocrine tumor in the U.S. According to the study published in the JAMA Oncology Journal, the survival rate for all neuroendocrine tumors has increased, especially for distant-stage gastrointestinal neuroendocrine tumors and pancreatic neuroendocrine tumors, owing to availability of effective treatments and early diagnosis.
View full press release